Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2004.323 | A Randomized, Open Label Trial of Telbivudine (LdT) versus Adefovir Dipivoxil in Adults with HbeAg-Positive, Compensated Chronic Hepatitis B | Dr. Leung Wai Yee Nancy |
| 2004.304 | A Randomized, Open Label Trial of Telbivudine (LdT) versus Adefovir Dipivoxil in Adults with HBeAg-Positive, Compensated Chronic Hepatitis B | Prof. Chan Lik Yuen Henry |
| 2012.305 | A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment. | Dr. WONG Raymond Siu Ming |
| 2005.248 | A Randomized, Open Label Study Evaluating the Efficacy and Safety of Peginterferon Alfa-2a (40KD) (PEGASYS_) or Adefovir Dipivoxil (ADV) in Patients with Lamivudine Resistant HBeAg Positive Chronic Hepatitis B | Prof. Sung JY Joseph |
| 2014.425 | A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy - SONAR: Study Of Diabetic Nephropathy with Atrasentan | Dr. OZAKI Risa |
| 2003.313 | A Randomized, Multicentre, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients with Mild-to-Moderate Dementia of the Alzheimer | Prof. Mok C.T. Vincent |
| 2017.606 | A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab versus no Prophylaxis in Hemophilia A Patients |
Prof. LI Chi Kong 李志光 |
| 2009.486 | A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer | Associate Professor Ma Brigette |
| 2017.320 | A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer |
Prof. YEO Winnie 楊明明 |
| 2016.534 | A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator’s Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2018.528 | A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER |
Prof. YEO Winnie 楊明明 教授 |
| 2024.271 | A randomized, multicenter, double-blind, Phase 3 study to investigate the safety and efficacy of belrestotug in combination with dostarlimab compared with placebo in combination with pembrolizumab in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1-selected non-small-cell lung cancer (GALAXIES LUNG-301) | Dr. LI Molly Siu Ching |
| 2018.333 | A Randomized, Multicenter, Double-Blind, Parallel-Group, Active-Control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy |
Prof SZETO Cheuk Chun 司徒卓俊 |
| 2008.248 | A Randomized, Multicenter Phase II Study to Explore Whether Biomarkers Correlate with Treatment Outcome in Chemo-Na・e Patients with Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer, Who Receive Treatment with Bevacizumab (at a dose of either 7.5 mg/kg or 15 mg/kg) in Addition to Carboplatin-based Chemotherapy (Gemcitabine or Paclitaxel) | Professor Mok Tony |
| 2002.328 | A Randomized, Multi-centre, Double-blind, Double-dummy, Parallel Group Trial of Two Doses of NNC 61-0029 in Combination with Glibenclamide Versus Glibenclamide Monotherapy and Versus Combination Therapy of Glibenclamide and Metformin in the Treatment of Subjects with Type 2 Diabetes | Dr. Chow Chun Chung Francis |
| 2001.233 | A Randomized, Multi-centre, Double-blind, Double-dummy, Parallel Group Trial of Two Doses of NNC 61-0029 in Combination with Glibenclamide Versus Glibenclamide Monotherapy and Versus Combination Therapy of Glibenclamide and Metformin in the Treatment of Subjects with Type 2 Diabetes | Dr. Chow C.C. Francis |
| 2019.458 | A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma |
Dr. CHAN Stephen Lam 陳林 |
| 2021.017 | A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination with Trans-arterial ChemoEmbolization (TACE) in Patients with Intermediate-stage Hepatocellular Carcinoma (HCC) |
Dr. CHAN Stephen Lam 陳林 |
| 2015.689 | A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma |
Prof. YEO Winnie 楊明明 |
| 2008.086 | A Randomized, International, Double-Blinded (With In-House Blinding), Controlled with GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16-to 26-Year-Old Women | Prof. CHEUNG Tak Hong |
| 2020.187 | A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration |
Dr. BRELÉN Mårten 柏倫 |
| 2009.389 | A randomized, double-masked, multicenter, laser-controlled Phase III study assessing the efficacy and safety of ranibizumab (intravitreal injections) as adjunctive and mono-therapy in patients with visual impairment due to diabetic macular edema | Dr Lee Yau Wing Vincent |
| 2017.327 | A randomized, double-masked, clinical trial comparing extended vs standard endonasal dacryocystorhinostomy (ExStEND) for primary acquired nasolacrimal duct obstruction |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2014.222 | A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Effectiveness of Atorvastatin in Patients with Chronic Subdural Haematoma | Prof. POON Wai Sang |
| 2005.110 | A Randomized, Double-blind, Two-arms Placebo-controlled, Parallel-group, Multicenter Study of Rimonabant 20mg Once Daily in the Treatment of Atherogenic Dyslipidemia in Abdoninally Obese Patients | Prof. Brian Tomlinson |
| 2006.158 | A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel-Group, Multicenter, Multinational Safety and Efficacy Trial of 300mg and 900mg of Abetimus Sodium in Systemic Lupus Erythematosus (SLE) Patients with A History of Renal Disease | Prof. Li Kwok Ming Edmund |
| 2014.269 | A randomized, double-blind, placebo-controlled, phase III, multi-centre study of eltrombopag or placebo in combination with azacitidine in subjects with IPSS intermediate-1, intermediate 2 and high-risk myelodysplastic syndrome (MDS) | Dr. WONG Raymond Siu Ming |
| 2003.398 | A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Oxaliplatin/5-Fluorouracil/Leucovorin with PTK787/ZK222584 or Placebo in Patients with Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum | Prof. Ma Buig Yue Brigette |
| 2015.540 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease |
Prof. LUK Andrea On Yan 陸安欣 |
| 2015.547 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2006.319 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ -333369 as Adjunctive Therapy in Subjects with Partial Onset Seizures Followed by an Open-Label Extension Study | Dr. Kwan Patrick |
| 2008.414 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects with Partial Onset Seizures, Followed by an Open-Label Extension Study | Prof. Kwan Patrick |
| 2010.200 | A Randomized, Double-Blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy | Prof. Tomlinson Brian |
| 2009.111 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared with Placebo in Subjects with Type 2 Diabetes Mellitus | Dr. Chow C.C. Francis |
| 2021.566 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in patients with non-diabetic chronic kidney disease | Prof. SZETO Cheuk Chun |
| 2018.122 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneously Administered Tafoxiparin as an Adjuvant to Induction Therapy in Term Pregnant, Nulliparous Women with an unripe cervix |
Prof. LEUNG Tak Yeung 梁德楊教授 |
| 2012.481 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome | Prof. YAN Bryan Ping Yen |
| 2001.489 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Study of The Therapeutic Effect And Safety Of A Traditional Chinese Medicine (TCM) For Atopic Dermatitis In Children | Prof. HON Ellis Kam Lun |
| 2002.013 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Pros. Study to Evaluate the Effect of a Herbal Preparation With Compound Formula of Danshen and Radix Puerariae as Cardiovascular Tonic in Cardiac Patient | Prof. Woo Kam Sang |
| 2002.179 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial Assessing The Rate of Decline of Lung Function with Tiotropium 18mcg Inhalation Capsule Once Daily in Patients with Chronic Obstructive Pulmonary Disease(COPD) | Prof. Hui Shu Cheong David |
| 2007.025 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function with Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD) | Dr. Chan Hok Sum |
| 2017.612 | A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s Disease (AD) |
Prof. MOK Chung Tong 莫仲棠 |
| 2005.253 | A Randomized, Double-blind, Placebo-Controlled, Multicentre Phase 3 Study to Evaluate the Long-term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain | Prof. Gin Tony |
| 2005.272 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects (SB-767905/008) | Prof. Gin Tony |
| 2011.181 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BRIVARACETAM IN SUBJECTS (_16 TO 80 YEARS OLD) WITH PARTIAL ONSET SEIZURES | Professor Patrick Kwan |
| 2019.039 | A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive Brivaracetam in Asian Subjects (≥16 to 80 years of age) with partial seizures with or without secondary generalization |
Dr. LEUNG Ho Wan 梁浩雲醫生 |
| 2012.474 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | Prof. WONG Samuel |
| 2012.479 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | Prof. LEE Alex Pui Wai |
| 2012.480 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | Dr. OZAKI Risa |
| 2012.488 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | Dr. TSANG Chiu Chi |
Page 215 of 254.